Monday, 10 June 2019

Age Related Macular Degeneration Market - Granular Market Report and Review, 2019

As per the study offered by Market Research Future (MRFR), the global age related macular degeneration market is set to expand at a CAGR of 8.3% during the forecast period 2018 to 2023. The valuation of the market is predicted to grow from USD 1.37 Bn at the end of 2017 to 2.21 Bn by 2023-end. The growing patient pool of a geriatric population is leading the expansion of the market. It is estimated that AMD contributes significantly towards visual loss among the elderly population. In addition, the global aging population is expected to get doubled by the end of 2020. It is presumed to aid the proliferation of the age related macular degeneration market over the assessment period.
The market is lucrative at present, and the rising awareness about the diseases is further expected to boost the growth trajectory of the age related macular degeneration market in the foreseeable future. On the flip side, unfavorable reimbursement policies and the high cost of drugs remain impediments to the market growth.
The expiry of drug patents for widely accepted branded drugs have opened new avenues of growth opportunities for the market participants. Investments are prognosticated to flow towards the development in the formulas of existing drugs for enhanced efficiency. In addition, expired drug patents have paved the way for a reduction in price points, thus, augmenting the global age related macular degeneration market.
Competitive Dashboard:
  • Regeneron Pharmaceutical Inc.,
  • Rxi Pharmaceuticals,
  • Hoffmann-La Roche AG,
  • Santen Pharmaceuticals
  • Bayer AG,
  • Pfizer Inc.,
  • Allergan,
  • Novartis AG,
  • Bausch & Lomb Incorporated,
  • Alimera Sciences.
Market Segmentation:
By type, the global age related macular degeneration market has been segmented into wet AMD and dry AMD.
By diagnosis & treatment, the age related macular degeneration market has been segmented into treatment and diagnosis.
By route of administration, the global age related macular degeneration market is segmented into intravitreal, intravenous, and others.
By stages, the age related macular degeneration market has been segmented into intermediate AMD, early AMD, and late AMD.
By age group, the global age related macular degeneration market has been segmented into above 75, above 60, and above 40.
By end-user, the age related macular degeneration market has been segmented into hospitals & clinics, diagnostic centers, academic research institutes, and others.
Regional Analysis:
The age related macular degeneration market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas is projected to hold a dominant share of the global market through the forecast period. The rising burden of the disease in the region is expected to drive the proliferation of the regional market. According to the Centers for Disease Control and Prevention (CDC), 1.8 million people were suffering from the disease in 2015 in the U.S.
Europe is an important growth pocket placed at the second position in the marketplace. It is predicted to benefit from rising geriatric population and increasing healthcare expenditure. Meanwhile, Asia Pacific is likely to emerge as the fastest growing regional market for AMD over the assessment period. The factors that are responsible for favoring the expansion of the age-related macular degeneration market in the region are rising healthcare expenditure, increasing prevalence of eye-disorders, growing geriatric population, etc.
Industry News:
In November 2018, the European Court of Justice has determined that Avastin by Roche can be reimbursed for the treatment of age-related macular degeneration despite the challenge imposed by Bayer and Novartis.
In December 2018, the U.S. based Ophthotech Corp. has scrapped the clinical trials of C5 inhibitor for the treatment of wet age-related macular degeneration in spite of successful phase 2a results exhibiting tolerance for imura (avacincaptad pegol) in combination with ranibizumab (Lucentis).
In December 2018, a team of British scientists has announced that they are piloting an eye drop aimed at treating age-related macular degeneration (AMD). The researchers have concluded successful trials on rabbits and pigs and will be tried on human eyes in 2019.
Browse Complete 220 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736


         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Acromegaly Market to show steady growth, 2019

The major driving factors for the market are increasing prevalence of acromegaly, changing lifestyle, and increasing genetic incident of genetic diseases. Moreover, increasing prevalence of hormonal diseases, for instance, endocrine diseases, and hypopituitarism, increasing government support and rapid developments in technology have fuelled the growth of the market. On the other hand, surgical costs is high, which ranges from approximately USD 2,800 to USD 9,200, however, when averaged it is less than the cost of medications. Unavailability of precise treatment and high cost of the surgery may restrain the growth of the market.
The Global Acromegaly Market is expected to grow at a CAGR of ~5.2 % during the forecast period 2017-2023.
Acromegaly is a hormonal disorder that results from heavy secretion of growth hormones (GH) in the body. The pituitary gland in the brain, secretes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called adenomas. Acromegaly is one of the rare diseases, which most often diagnosed in the middle-aged adults and affects 5-8 people per 1 lakh people. If the diseases is not treated, it can result in serious illness and premature death. The most serious health consequences of the disease may result into high blood pressure, type 2 diabetes, increased risk of cardiovascular disease, arthritis, and others.
Key Players
  • Novartis AG (Switzerland),
  • Aegis Therapeutics LLC (US),
  • Chiasma Inc (US),
  • Crinetics Pharmaceuticals Inc (US),
  • Daewoong Pharmaceutical Co Ltd (South Korea),
  • Peptron Inc (South Korea),
  • Silence Therapeutics Plc (UK),
  • Strongbridge Biopharma plc (US),
  • Amryt Pharma plc (UK),
  • Foresee Pharmaceuticals LLC (US),
  • Glide Pharmaceutical Technologies Ltd (US),
  • Ionis Pharmaceuticals Inc (US),
  • Ipsen SA (France)
Segmentation
Acromegaly market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of treatment, the market is segmented into medications, surgery, radiation therapy, and others. The medication is further segmented into somatostatin analogues, dopamine agonists, growth hormone receptor antagonists, and others. The surgery is further segmented into endonasal transphenoidal surgery, and transphenoidal surgery.
On the basis of diagnosis, the market is segmented into medical imaging, medical laboratory investigations, others. The medical imaging is further segmented into radiography, magnetic resonance imaging (MRI), nuclear medicine, ultrasound, and others.
On the basis of type, the market is segmented into ectopic acromegaly, acromegaly due to growth hormone, and others.
Regional Analysis
Asia Pacific is the fastest growing acromegaly market. China, and India are the significant contributors to the market growth due to the presence of huge population base, increasing prevalence of acromegaly, rapidly growing healthcare sector, and increasing healthcare expenditure. Whereas, the Middle East & Africa holds the least share of the global market due to poor economic condition and limited availability of medical facilities in African region. The Middle East & African acromegaly market is majorly driven by the UAE, Saudi Arabia, and Kuwait.
The Americas commands the global market owing to increasing prevalence of acromegaly, large patient population, high healthcare spending, and strong government support for research & development. According to the Health Research Funding Organization, in America, over 3,000 new cases of acromegaly occurs per year.
Europe leads the second position of the global the market, which is followed by Asia Pacific. High healthcare expenditure, well developed healthcare sector, and increasing government support drives the growth of the market.
Browse Complete 67 Pages Premium Research Report Enabled with Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/acromegaly-market-4429
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Friday, 7 June 2019

India CRO Market 2019 - Opportunity, Driving Trends and deep study 2023

According to the analysis offered by Market Research Future (MRFR), the India CRO market has been presumed to flourish at a CAGR of 12.0% during the forecast period.
A Contract Research Organization (CRO) offers outsourced services to support R&D functions for pharmaceutical, biotechnology, and health companies. The services may be clinical research, product development such as drug development or process development such as bio analytical assay development. A CRO may also provide management services such as clinical trials management, and pharmacovigilance.
India has rapidly become one of the preferred destinations for clinical trials owing to its large heterogeneous patient pool, rapidly transforming healthcare market, highly educated physicians and cost competitiveness propels the market growth. In addition, increased investment from foreign companies as well as local market players either individually or in collaboration is likely to boost the market growth during the forecast period. Further, emerging research areas such as diagnostic research are expected to fuel the India CRO market.
The India CRO market restraints are rising concern for security especially data security and patient security in clinical trials, lack of collaboration between universities and industry. Further, the compromises done by some India CROs on ethical and technical standards are the major market threat.
The two important factors that are making India a favorable market for CRO include India’s acceptance of international guidelines and intellectual property rights. Other factors include the availability of the largest pool of patients and large hospitals, educated and accessible human resource (HR), low operational cost due to cheap HR, and lastly the presence of diverse types of climatic conditions that allow stability studies to be performed with ease in one destination. Some legal factors that favor the growth of India CRO market are efforts by the regulatory authorities such as Department of Biotechnology (DBT), Director Controller General of India (DCGI), Directorate General of Foreign Trade (DGFT), and Indian Council of Medical Research (ICMR).
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Regional Analysis of India CRO Market:
The healthcare sector of India is divided between differential geographic regions and states. The South India and western India account for a major share of the Indian CRO market. However of late the CRO industry is shifting to the North. The reasons for this shift is the concentration of regulatory authority such as Director Controller General of India (DCGI) office, Indian Council of Medical Research (ICMR), Directorate General of Foreign Trade (DGFT), Department of Biotechnology (DBT) etc. Also the costs are lower in North India and the genetic pool is more diverse.
India is emerging as a top destination for contract research organizations for the following reasons
  • India’s acceptance of International guidelines and intellectual property rights
  • Presence of diverse types of climatic conditions thus allowing stability studies to be performed with ease in one destination
  • Educated and accessible human resource in India
  • Presence of diverse ethnic pool thus enabling diverse sample for clinical trials
  • Low operational cost due to cheap human resource
  • Availability of largest pool of patients and large hospitals

Indian CRO Market - Competitive Landscape
The India CRO market is dominated by multinational CROs, followed by India CROs, multinational pharmaceutical companies, and Indian pharmaceutical companies. Among these, the Indian pharmaceutical companies are mainly engaged in conducting local trials.
In March 2018, The world's largest healthcare information provider and contract medical research, IQVIA, has recently stated that it is preparing to initiate outright buyouts to investments in start-ups for technologies that based on artificial intelligence and data analytics, while also considering those related to the healthcare sector as it converts into a "Human Data Science Company". Further, the company also stated that the investments in the future will be more directed towards development in the Asia Pacific region that includes China, India, Japan and South Korea where the company forecasts increasing demand for its services in the coming years.
In March 2018, Syngene International has entered into a multiyear R&D agreement with GlaxoSmithKline plc. The companies with this collaboration are focus to accelerate the discovery of new drug candidates using Syngene discovery services platforms.
Browse Complete 70 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/india-cro-market-2927
Detailed Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
9 Company Landscape
9.1 Introduction
9.1.1 Mergers Acquisitions
9.1.2 Collaborations
9.1.3 Release/New Product Launches
9.1.4 Other (Expansion, Updates, Partnership)
10 Company Profile
10.1 Quintiles IMS Holdings, Inc.
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financials
10.1.4 Key Developments
10.1.5 SWOT Analysis
...TOC Continued!


         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Bone Scan Market Pipeline Review, 2019- Identify Key Business Opportunities

According to the WHO, about 59% of the mortality is due to chronic diseases and almost 35 million people die of chronic diseases across the globe.
The global bone scan market is expected to grow at a CAGR of 5.7% during the forecast period.
A bone scan is a test of nuclear medicine and is mostly used to diagnose various bone diseases such as arthritis and bone cancer. It includes an injection of radioactive material and then the bone scan. Radioactive material also known as the tracer is injected into a vein. After injecting this material, the radiologist performs a bone scan. The radiologist may perform the bone scan in phases depending upon the condition to be diagnosed such as the presence of bone disease or cancer.
Rising prevalence of bone disease, increasing demand for imaging devices such as MRI, CT scan, SPECT scan, and increasing health care services are accelerating the growth of the market. Furthermore, the increasing expenditure on medical devices influences the market growth. Technological advancements in radiology devices affecting the market growth. However, the efficiency of bone scan may hinder the market growth over the forecast period. Additionally, the bone scan may determine the inaccurate cause of the abnormality.
Key Players in the Global Bone Scan Market   
  • Siemens (U.S.)
  • Hitachi, Ltd. (Japan)
  • Carestream Health, Inc. (U.S.)
  • Samsung Electronics Co., Ltd. (South Korea)
  • Toshiba Corporation. (Japan)
  • Koninklijke Philips N.V. (Netherlands)
  • General Electric Company (U.S.)
Segments of the Global Bone Scan Market
The global bone scan market is segmented on the basis of product, indication, device, and end user.
On the basis of the product, the market is segmented into radiopharmaceuticals and imaging devices. The imaging devices are further segmented into Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and others.
On the basis of the application, the market is segmented into fractures, arthritis, Paget's disease of bone, cancer originating in bone, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis
The Americas lead the global bone scan market owing to the rising prevalence of bone disorders in the U.S. Furthermore, increasing demand for diagnostic services in various also influences the market growth. In North America, the U.S. is the largest market followed by Canada. Increasing penetration of orthopedic specialty hospitals and healthcare insurance is adding fuel to the market growth. Furthermore, the concentration of key players in the market along with the availability of various technologically advanced devices is boosting the market growth in the U.S.
Europe is the second largest bone scan market across the globe. The market is accelerated by the extensive use of diagnostic devices for diagnosis of various chronic diseases such as arthritis, diabetes, obesity and others. Furthermore, extensive research and development (R&D) activities carried out by clinical research and academic institutes stimulate the growth of the market. Germany and France contribute to the growth of the market owing to increasing expenditure on R&D and extensive demand for diagnostic devcies.
The Asia Pacific market is expected to grow at the fastest pace due to the high prevalence of chronic disease such as rheumatoid arthritis, osteoarthritis, obesity, diabetes, and other. Additionally, increasing number of bone injuries such as bone fractures boost the growth of the market.  To add further, increasing number of skilled professionals along with increasing awareness about the bone diseases and importance of imaging tests in the diagnosis of bone diseases, and injuries. In Asia Pacific, India and China are holding the largest market share followed by Japan. Increasing expenditure on healthcare and improving healthcare infrastructure in various developing regions of Asia Pacific region are affecting the market growth, positively.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bone-scan-market-5027

TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
…TOC Continued!

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Thursday, 6 June 2019

Biochips Market Research Report 2019 Analysis and Forecast to 2023

Market Scenario:
Global Biochips Market held a market value of USD 7,300 million in 2017, according to the latest research report from Market Research Future (MRFR). The market is expected to exhibit a strong 16.6% CAGR over the forecast period from 2018 to 2023, according to the report.
Biochips are intended to function in biological environment, preferably inside living organism. The factors such as increasing technological advancements in biochips is the major driving factor for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer genomics. Furthermore, growing applications of biochips will boost the market growth during forecast period. For instance, biochips can perform thousands of biological reactions operations in few seconds.  
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7063            
However, high cost of the instruments and stringent regulatory guidelines may restrain the growth of the market.
According to national Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
Competitive Landscape:Perkinelmer, Inc., Fluidigm Corporation, Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid Inc., Illumina, Inc., GE Healthcare, Thermo Fisher Scientific, Inc, Roche Diagnostics are some of the prominent players in the global biochips market.
Segmentation:The Global Biochips Market has been segmented into type, technology, and end user.
By type, the market has been segmented into DNA chips, lab-on-a-chip, protein chips, cell arrays, and tissue arrays. DNA chips is further segmented into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, drug discovery, agricultural biotechnology, and others. Lab-on-a-chip is further segmented into clinical diagnostics, genomics, IVD (In-Vitro Diagnostic) & POC (Point of care), Proteomics, Drug Discovery, and others. Protein chips is further segmented into proteomics, expression profiling, diagnostics, high-throughput screening, drug discovery, others.
Based on technology, the market has been segmented into microarrays and microfluidics.
The biochips market, by end user, has been segmented into biotechnology and pharmaceutical companies, hospitals and diagnostics centers, academic & research institutes, and others.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global biochips market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the global biochips market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The biochips market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biomedical and biotechnology sector and growing number of target population in the region.  
The Middle East & Africa has the lowest share of the global biochips market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.  
         

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Animal Genetics Market Growth and Restrain Factors Analysis By 2023

Market Scenario:
Animal genetics is a branch of genetics that pacts with the study of genetic variation and inheritance, primarily for domestic and wild animals. For the commercial level, animal genetics is used for services such as DNA typing, genetic disease testing, and genetic trait testing. This methodology uses hybrid population, ontogenetic, and cytological studies for determining the genetic hybridizations. For instance, a genetically modified cow might be able to produce more milk and can be less prone to common cattle diseases, such as clostridial disease, bovine respiratory disease complex, etc., thus, effectively increasing overall profit of the cattle farmers.
The Global Animal Genetics Market size is projected to register a CAGR of 8.4% over the forecast period.
The key factor responsible for influencing this market is increasing consumption of animal-derived protein, growing global population and rapid urbanization, and growing focus on identifying superior breeds have aided the growth of the toxicology testing market. However, factors such as, the high cost of animal testing, stringent regulatory framework for genetic engineering, and lack of skilled professionals and are expected to restrict the market growth during the forecast period.

Key players:
  • Neogen Corporation (US),
  • Genus (UK),
  • URUS (US),
  • EW Group (Germany),
  • Groupe Grimaud (France),
  • CRV Holding B.V. (The Netherland),
  • Topigs Norsvin (Netherlands),
  • Zoetis (US),
  • Envigo (US)
  • Hendrix Genetics BV (The Netherland),
  • Animal Genetics (US),
  • Alta Genetics (US),
  • vetGen (US)
Segmentation:The Global Animal Genetics Market is segmented into animal genetic products, services, and end-user. The Animal Genetics Market, by animal genetic products, the market is segmented into genetic materials and live animals. The live animals are further bifurcated into poultry, bovine, porcine, canine and others. The genetic materials are sub-segmented into semen and embryo. On the basis of services, the animal genetics market is bifurcated into genetic disease tests, DNA typing, gene trait tests, and others. On the basis of end-user, the market is segmented into veterinary hospitals & clinics, diagnostic centers, research centers and institutes, and others
Regional Market Summary 
The Americas is the largest in the market owing to the high acceptance of animal genetics in research, the development in research expenditure along with the increasing acquisition by the market players are also accountable for the growth of the animal genetics market. For instance, in 2018, Neogen completed the acquisition of Livestock Genetic Services, a firm that specializes in genetic evaluations and data management for cattle-breeding organizations. This strategy enhances the company’s in-house genetic evaluation capabilities and further expands the company’s global network of animal genomics laboratories.
The European region is the second largest animal genetics market over the forecast period due to high consciousness about animal wellbeing coupled with increased expenditure on veterinary services in the region. As per a report by the European Pet Food Industry Federation, more than 75 million households in Europe own a pet.
The Asia Pacific region is likely to develop at the uppermost CAGR for the animal genetics market in the years to come. Moreover, the rising veterinary care services both at the veterinary hospital and at community level are expected to influence the market in a positive way.
The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of animal genetic technology in this region.

 


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Genetic Testing Market - Granular Market Report and Review, 2019

Market Scenario:
The Global Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024. Some of the protuberant drivers supporting the growth of the global genetic testing market are identified as raising awareness about the benefits of genetic testing and the rising prevalence of genetic disorders.
Additionally, the role of genetic tests in forensic investigations and change in the trend of the genetic testing industry from service-driven to product-driven industry are expected to drive the global genetic testing market in the coming years.
Genetic testing is also known as DNA testing. Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders. Genetic testing offers a lot of benefits such as the chance for taking preventive measures to avoid potential diseases and lead a healthy life, knowledge about genetic alterations in the fetus that may lead to abnormal growth, and aids forensic investigations, among others. Due to the great benefits provided by these tests, people are getting more aware of them. This phenomenon intrigues people to go for tests to understand their genetic structure and possible disorders they may have to go through. The growing awareness has gathered a lot of audience for the genetic testing market and has also positively impacted the growth of this market.
Moreover, there has been tremendous growth in the prevalence of genetic disorders which may be due to various reasons such as geographical and environmental changes, change in food habits, pollution, and exposure to harmful radiations or chemicals. Genetic tests are also used to analyze family relations such as father, mother, half-brother, half-sister, and others. Forensic science and genetic testing have aided law and order to a great extent. With an increasing number of companies entering into this segment, the overall market for genetic tests has increased and expected to grow fast in the near future.
Key Players
The prominent players in the global genetic testing market are Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).
Some of the key strategies followed by the players operating in the global genetic testing market were innovation, product development, acquisition, and expansion.
  • In April 2017, Myriad Genetics, Inc. signed an agreement with Clovis Oncology for the use of its FDA-Approved BRACAnalysis CDx Test to identify patients with germline BRCA Mutations for the Rubraca (rucaparib) treatment.
  • In January 2017, Bio-Rad Laboratories, Inc. announced the launch of the Single Cell Sequencing Solution in collaboration with Illumina Inc.
  • In August 2016, Abbott Laboratories launched Alinity, a family of next-generation system.
Segmentation                                                                                                                                        
Global genetic testing Market, by type, segmented into prescribed genetic testing and direct to consumer genetic testing. Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024. Its large market share is majorly attributed to the widespread availability and service providers of various genetic tests and less availability of direct to consumer tests in all parts of the world.
Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period. Molecular testing helps to determine the sequence in DNA or RNA related to a particular disease.
The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.
Regional Analysis         
The Americas accounted for the largest market share of the global genetic testing market, by region in 2018. This large share is majorly due to high awareness about genetic testing, high disposable income of the population, and implementation of newborn screening in the majority of the hospitals in the region. In 2015, approximately 12 million Americans suffered from genetic diseases which are approximately 1 in 20 people.
Europe accounted for the second largest market share. Technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices have provided fuel for the growth of the market. Germany commands the largest market share in the Europe genetic testing market.
Asia-Pacific is the fastest growing region for genetic testing. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the Asia-Pacific genetic testing market. The Middle East & Africa accounted for the 8.8% market share in 2018.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)